Whitehawk Therapeutics (WHWK) Operating Income (2018 - 2025)
Historic Operating Income for Whitehawk Therapeutics (WHWK) over the last 8 years, with Q3 2025 value amounting to -$19.5 million.
- Whitehawk Therapeutics' Operating Income fell 4572.43% to -$19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$108.5 million, marking a year-over-year decrease of 6378.3%. This contributed to the annual value of -$67.5 million for FY2024, which is 622.11% up from last year.
- Latest data reveals that Whitehawk Therapeutics reported Operating Income of -$19.5 million as of Q3 2025, which was down 4572.43% from -$54.7 million recorded in Q2 2025.
- In the past 5 years, Whitehawk Therapeutics' Operating Income ranged from a high of -$3.9 million in Q2 2021 and a low of -$87.3 million during Q3 2021
- Moreover, its 5-year median value for Operating Income was -$16.8 million (2023), whereas its average is -$21.2 million.
- Its Operating Income has fluctuated over the past 5 years, first crashed by 317867.07% in 2021, then skyrocketed by 8277.88% in 2022.
- Whitehawk Therapeutics' Operating Income (Quarter) stood at -$15.9 million in 2021, then increased by 2.97% to -$15.5 million in 2022, then fell by 14.49% to -$17.7 million in 2023, then dropped by 6.97% to -$18.9 million in 2024, then dropped by 3.15% to -$19.5 million in 2025.
- Its Operating Income stands at -$19.5 million for Q3 2025, versus -$54.7 million for Q2 2025 and -$15.2 million for Q1 2025.